The role of patient preferences in Market Access

Learn how HTAs, HCPs and patients’ associations value patient preferences

10. Nov 2021

1 day event

Danish

0 DKK ex VAT
(app. 0 EUR ex VAT)
50% DISCOUNT FOR PUBLIC INSTITUTIONS

Summary

Approval bodies such as the FDA, EMA and NICE will soon focus on patient preference evidence when approving new medical treatments. It is therefore inevitable that pharma HQs will begin generating such evidence and expecting affiliates to utilize such evidence in Market Access and Commercial work.

At this course you gain an understanding of what Patient Preferences is, which methods to generate and measure patient preferences and how they can be used in a Danish context when working with Payers, HCPs and patient organizations.
 

Key words

  • Patient preferences
  • Patient Advocacy
  • Medical Affairs
  • Market Access
  • Stakeholder management
  • Health data
  • Evidence
  • Medicine evaluation
  • Danish Medicines Council

Hi! Do you need help choosing the right course?

We are ready to help you at +45 39 27 60 60 or contact@atriumcph.com

Read more

Course leader(s) & Lecturers

  • Arun Micheelsen
    Course leader
    Chefkonsulent
    DLI Market Intelligence ApS
  • Elisabeth Gammelgaard Ludvig
    Course leader
    Owner
    Sundhedsagenda
  • Agathe Le Lay
    Lecturer
    Senior Director and Global Head of Value Evidence
    Lundbeck A/S
  • Leif Vestergaard Pedersen
    Lecturer
    Danske Patienters repræsentant
    Medicinrådet
  • Karina Dahl Steffensen
    Lecturer
    Professor, Overlæge v. Onkologisk Afdeling og Leder af Center for Fælles Beslutningstagning
    Sygehus Lillebælt
  • Rie Stjærnholm Trærup
    Lecturer
    Brand Lead
    Bristol-Myers Squibb
  • Søren Esben Hansen
    Lecturer
    Senior Advisor
    DLI Market Intelligence ApS
See all

IS THIS COURSE FOR YOU?

This course is essential for you if you work with Medical Affairs, Market Access, Public Affairs, Sales, Marketing or Patient Advocacy.

Others interested in learning about patient preferences are also welcome.

What you will learn

  1. What patient preferences are and how they can be generated quantitatively and qualitatively
  2. How international approval bodies work with patient preferences, including the expectations of the Danish Medicines Council for the role played by the preferences in the Council's work in the future
  3. The relationship between HQ and subsidiaries regarding patient preferences
  4. How healthcare professionals and patients’ associations work with patient preferences in everyday life, and how pharmaceutical companies can contribute to that work

What your company will get

  1. An employee who understands patient preferences and how these can be utilised in cross-functional work during the product lifecycle from development and pre-approval to launch and post-launch
  2. An employee with knowledge about how patient preferences are included in approval bodies’ decision-making processes

Calendar

10. Nov 2021 9:00-16:00

DAY 1

  • A HQ’s work with patient preferences and its’ expectations for affiliates
  • The Danish Medicines Council view on patient preference data
  • How do physicians work with patient preferences and decision tools in the daily clinic?
  • Knowledge on patient preferences can improve the introduction of new treatment
  • Discussion and conclusions
Practical information

Registration

Registration deadline
3. Nov 2021
Atrium
Lersø Parkallé 101
2100 København Ø
Sold out
Sometimes things change. This is the expected programme.

Course information

Literature

Prior to the course you will get access to mandatory and optional readings via your personal Atrium log-in.

Please familiarize yourself with the mandatory readings before starting the course.

The mandatory readings are also part of the examination syllabus. 

Please download and read whitepaperet “The value of patient preference, DLIMI”. You can download it here.

Examination

There is no examination for this course.

Course leader(s)

Arun Micheelsen
Chefkonsulent
DLI Market Intelligence ApS
Elisabeth Gammelgaard Ludvig
Owner
Sundhedsagenda

Lecturers

Arun Micheelsen
Chefkonsulent
DLI Market Intelligence ApS
Agathe Le Lay
Senior Director and Global Head of Value Evidence
Lundbeck A/S
Leif Vestergaard Pedersen
Danske Patienters repræsentant
Medicinrådet
Karina Dahl Steffensen
Professor, Overlæge v. Onkologisk Afdeling og Leder af Center for Fælles Beslutningstagning
Sygehus Lillebælt
Rie Stjærnholm Trærup
Brand Lead
Bristol-Myers Squibb
Søren Esben Hansen
Senior Advisor
DLI Market Intelligence ApS

You may also be interested in these courses

Want to know more or need help?

Contact Client Manager Birger Flinthagen at +45 39 15 09 06

Send me a message